Selinexor for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Jun 2022: Trial registered, NCT05432804
  2. 20 Mar 2023: Trial started, NCT05432804

The trials

NCT05432804: Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

State
Under way
Phase
Phase 1 and Phase 2
People
97 planned
Started
20 Mar 2023
Primary completion
30 Jun 2027
Arms
Group II (temozolomide, selinexor)
Results
None posted
  1. 27 Jun 2022: Trial registered
  2. 20 Mar 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Xpovio.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.